Abbott Laboratories (ABT) recently made Lingo, its continuous glucose monitoring (CGM) system, available in the United States without a prescription. The system comes with a biosensor and a mobile app designed for consumers’ overall health improvement and wellness.The latest U.S. availability of Lingo helps Abbott expand its market presence in the CGM segment.Following the news, shares of ABT fell 1.1% to $113.10 yesterday. However, as the company is gaining a high level of synergies from its continued deve ...